Who makes GSK1838262 600 mg?

GSK1838262 600 mg is developed by XenoPort, Inc..

What development phase is GSK1838262 600 mg in?

GSK1838262 600 mg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

GSK1838262 600 mg

XenoPort, Inc. · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	GSK1838262 600 mg
Also known as	Horizant, gabapentin enacarbil GEn, XP13512
Sponsor	XenoPort, Inc.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (PHASE4)
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome (PHASE2)
Prevention Study in Adult Patients Suffering From Migraine Headaches (PHASE2)
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects (PHASE1)
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK1838262 600 mg CI brief — competitive landscape report
GSK1838262 600 mg updates RSS · CI watch RSS
XenoPort, Inc. portfolio CI